Diabetes and Hypertension
Research examined kidney endpoints between patients with type 2 diabetes after initiating an SGLT2i or GLP-1RA.
In a Kidney Action Week session, Drs. Swapnil Hiremath and Jordana Cohen discussing management of resistant high BP with CKD.
SC0062 met the 12-week primary end point of a reduction in proteinuria in a study cohort with diabetic kidney disease (DKD).
A team analyzed sotagliflozin's effects on hemoglobin in patients with stage 3-4 CKD and type 2 diabetes.
Do GLP-1 receptor agonists reduce the risk of important clinical outcomes? Can patients without diabetes benefit from them?
The FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes.
A secondary analysis of DCP trial data sought to understand the effects of thiazide diuretics on kidney outcomes.
The renal effects and safety of acetazolamide in patients with type 1 diabetes was the subject of a recent study.
A study evaluated kidney outcomes of ARNI therapy versus ACEI/ARB for TMA related to malignant hypertension.
A study examined an association between hyperglycemic crises at diabetes diagnosis and a higher risk of developing CKD.
The accuracy of continuous glucose monitoring versus self-monitored blood glucose in hemodialysis patients is not well known.
Direct comparisons of kidney and cardiovascular outcomes with GLP-1 RAs and SGLT2i in type 2 diabetes are lacking.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.